Hosking Partners LLP grew its position in Bristol-Myers Squibb Co (NYSE:BMY) by 7.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 206,959 shares of the biopharmaceutical company’s stock after buying an additional 14,440 shares during the quarter. Hosking Partners LLP’s holdings in Bristol-Myers Squibb were worth $12,682,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Advisor Partners LLC lifted its holdings in shares of Bristol-Myers Squibb by 6.9% in the 3rd quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock worth $2,356,000 after buying an additional 2,382 shares during the period. Oppenheimer & Co. Inc. lifted its stake in shares of Bristol-Myers Squibb by 2.5% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock worth $19,976,000 after purchasing an additional 8,813 shares during the last quarter. Israel Discount Bank of New York lifted its stake in shares of Bristol-Myers Squibb by 31.8% during the 2nd quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock worth $586,000 after purchasing an additional 2,540 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Bristol-Myers Squibb by 0.7% during the 3rd quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock worth $50,436,000 after purchasing an additional 5,451 shares during the last quarter. Finally, Aperio Group LLC lifted its stake in shares of Bristol-Myers Squibb by 12.7% during the 3rd quarter. Aperio Group LLC now owns 854,457 shares of the biopharmaceutical company’s stock worth $54,463,000 after purchasing an additional 96,561 shares during the last quarter. Institutional investors and hedge funds own 71.49% of the company’s stock.
Shares of Bristol-Myers Squibb stock opened at $66.60 on Monday. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $70.05. The company has a market capitalization of $108,730.02, a PE ratio of 22.13, a price-to-earnings-growth ratio of 2.05 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period last year, the business posted $0.63 earnings per share. The firm’s revenue was up 3.9% compared to the same quarter last year. equities research analysts predict that Bristol-Myers Squibb Co will post 3.2 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 271.19%.
A number of equities research analysts recently weighed in on the company. TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. ValuEngine cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Bank of America upped their price objective on Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a research note on Monday, March 5th. DZ Bank cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, February 28th. Finally, Jefferies Group set a $72.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, February 26th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $66.30.
TRADEMARK VIOLATION NOTICE: “Hosking Partners LLP Raises Holdings in Bristol-Myers Squibb Co (BMY)” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2018/03/19/hosking-partners-llp-raises-holdings-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.